I just recently had this blood work done. Can you explain it Comp panel: Leukemia/Lymphoma NAME VALUE LAB F Flow Interpretation -Y - 1) No significant immunophenotypic abnormality detected - 2) Absolute lymphocytosis, see comment F Flow Comment -Y - The lymphocytosis is due to an absolute increase in B cells and CD4+ T - cells. Increases in multiple lymphocyte subsets suggests a reactive - process. Clinical correlation is recommended. F Clinical Information -Y - Leukocytosis - A recent CBC has been reviewed in preparing this report. It shows - leukocytosis and lymphocytosis. F Specimen Type -Y - Peripheral blood F Assessment of Leukocytes -Y - No monoclonal B cell population is detected. kappa:lambda ratio 2.4 - There is no loss of, or aberrant expression of, the pan T cell antigens to - suggest a neoplastic T cell process. - CD4:CD8 ratio 2.1 - No circulating blasts are detected. - There is no immunophenotypic evidence of abnormal myeloid maturation. - Analysis of the viable lymphocyte population shows: B cells 14%, T cells - 78%, NK cells 8%. F Viability -Y - 80% F Analysis and Gating Strategy -Y - 8 color analysis with CD45/SSC gating F Phenotype Chart -Y - CD2 Normal CD3 Normal - CD4 Normal CD5 Normal - CD7 Normal CD8 Normal - CD10 Normal CD11b Normal - CD13 Normal CD14 Normal - CD16 Normal CD19 Normal - CD20 Normal CD33 Normal - CD34 Normal CD38 Normal - CD45 Normal CD56 Normal - CD57 Normal CD117 Normal - HLA-DR Normal KAPPA Normal - LAMBDA Normal CD64 Normal F Resulting Path Name -Y - Shannon Covey, M.D. F Comment: TG - Each antibody in this assay was utilized to assess for potential - abnormalities of studied cell populations or to characterize - identified abnormalities. - . - This test was developed and its performance characteristics determined - by LabCorp. It has not been cleared or approved by the U.S. Food and - Drug Administration. - . - The FDA has determined that such clearance or approval is not - necessary. This test is used for clinical purposes. It should not be - regarded as investigational or for research.